The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Pre-transplant salvage options: bringing conventional versus novel combinations to practice
Featured:
Alison MoskowitzDuring ASCO 2019, Chicago, US, Alison J Moskowitz, Memorial Sloan Kettering Cancer Center, New York, US, spoke to the Lymphoma Hub about pre-transplant salvage options: bringing conventional versus novel combinations to practice.
Dr. Moskowitz explains that the general approach for a patient that has relapsed or refactor disease after their frontline treatment for Hodgkin lymphoma (HL) is to give some kind of second-line therapy followed by consolidation with an autologous stem cell transplant and the choice of treatment is dependant upon the institution treating the patient. These treatments may include traditional therapies such as ICE, chemotherapy, or DHAP based regimes. However, now that there are newer regimes available for HL such as rituximab and checkpoint inhibitors these are now being considered when treating second-line therapy patients.
Pre-transplant salvage options: bringing conventional versus novel combinations to practice